Author(s)

Yan Fan, Wenmin Cai, Sawei Li, Lulu Zhang

Corresponding Author

Yan Fan

Abstract

Objective: To investigate the application of Ubumex combined with AC-T sequential chemotherapy in the treatment of triple negative breast cancer (TNBC). Methods: From January 2016 to January 2018, 92 patients with TNBC were enrolled. According to the random number table, the patients were divided into observation group and control group, with 46 cases in each group. The control group received a simple AC-T sequential chemotherapy regimen, and the observation group was treated with Ubumex. The clinical efficacy, serum T lymphocyte subsets and osteopontin (OPN) levels and quality of life improvement before and after treatment were compared. Results: The total effective rate of the observation group was 91.30% (42/46) higher than that of the control group 76.09 (35/46, P<0.05). There was no significant difference in serum T lymphocyte subsets and OPN levels between the two groups before treatment (P>0.05). The level of T lymphocyte subsets in the observation group was higher than that in the control group, and the OPN level was lower than that in the control group (P<0.05). The improvement rate of quality of life in the observation group was 54.35% (25/46) higher than that in the control group (32.61%). Conclusion: Ubumex combined with AC-T sequential chemotherapy in the treatment of TNBC is effective, can effectively improve the body's immune function, down-regulate the expression of serum OPN, and improve the quality of life of patients.

Keywords

Triple-Negative Breast Cancer, Ac-T Sequential Chemotherapy Regimen, Ubumex, T Lymphocyte Subsets, Opn Levels